-
公开(公告)号：US20070280951A1
公开(公告)日：2007-12-06
申请号：US10582304
申请日：2004-12-10
IPC分类号： A61K39/395 , A61P35/00 , A61P37/00 , C07H21/00 , C07K16/00 , C12N1/00 , C12N15/63 , C12N5/00 , C12P21/00
CPC分类号： C07K16/00 , C07K2317/622 , C07K2317/73
摘要： The present inventors constructed a DNA expression vector encoding 2D7sc(Fv)2 in which the heavy chain variable region sequence (VH) and the light chain variable region sequence (VL) of the 2D7 antibody is arranged in the order of VH-VL-VH-VL, and these sequences are linked by a 15-mer linker. The vector was introduced into CHO cells and a 2D7sc(Fv)2-producing expression cell line was established. When 2D7sc(Fv)2 was expressed in this cell line, purified, and cell death-inducing experiments performed, 2D7sc(Fv)2 was found to have a concentration-dependent cell death-inducing activity.
摘要翻译： 本发明人构建了编码2D7sc（Fv）2的DNA表达载体，其中2D7抗体的重链可变区序列（VH）和轻链可变区序列（VL）以VH-VL-VH -VL，并且这些序列通过15聚体连接子连接。 将载体导入CHO细胞，并建立产生2D7sc（Fv）2的表达细胞系。 当在该细胞系中表达2D7sc（Fv）2时，发现2D7sc（Fv）2的纯化和细胞死亡诱导实验具有浓度依赖性细胞死亡诱导活性。
-
公开(公告)号：US20070172488A1
公开(公告)日：2007-07-26
申请号：US11702780
申请日：2007-02-05
IPC分类号： A61K39/395
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734
摘要： Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.
摘要翻译： 本发明提供可用于治疗基于异常细胞增殖，特别是癌症的疾病的细胞生长抑制剂。 细胞生长抑制剂含有磷脂酰肌醇蛋白聚糖3抗体作为活性成分。
-
公开(公告)号：US20070003556A1
公开(公告)日：2007-01-04
申请号：US10550934
申请日：2004-03-31
申请人： Masayuki Tsuchiya , Naoki Kimura , Tatsuya Fukuda
发明人： Masayuki Tsuchiya , Naoki Kimura , Tatsuya Fukuda
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/2803 , C07K2317/622 , C07K2317/73
摘要： CD22 diabodies, in which heavy-chain and light-chain variable regions are linked by a 5-mer linker, were produced based on known sequence information for two types of anti-CD22 antibodies. The two diabodies produced were analyzed for their activity of binding to lymphoma cells and inducing lymphoma cell death (apoptosis). As a result, both diabodies were revealed to bind to the B-lymphoma cell line, “Raji”, and to have apoptosis-inducing activity towards Raji cells as well as towards another B-lymphoma cell line: Daudi cells. These results show that minibodies of antibodies that recognize CD22 can be used as apoptosis-inducing agents for tumor cells such as lymphoma cells.
摘要翻译： 基于两种类型的抗-CD22抗体的已知序列信息产生CD22双抗体，其中重链和轻链可变区通过5-聚体连接子连接。 分析所产生的两种双抗体与淋巴瘤细胞结合的活性，诱导淋巴瘤细胞死亡（凋亡）。 结果，双抗体被揭示结合到B淋巴瘤细胞系“Raji”，并且对Raji细胞以及另一B淋巴瘤细胞系具有凋亡诱导活性：Daudi细胞。 这些结果表明识别CD22的抗体的小体抗体可以用作肿瘤细胞如淋巴瘤细胞的凋亡诱导剂。
-
公开(公告)号：US07052873B2
公开(公告)日：2006-05-30
申请号：US09509098
申请日：1998-10-02
申请人： Masayuki Tsuchiya
发明人： Masayuki Tsuchiya
IPC分类号： C12N15/00
CPC分类号： C07K16/464 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/3061 , C07K2317/24 , C07K2317/732 , C07K2319/00
摘要： A reshaped human anti-HM1.24 antibody comprising: (A) L chains each comprising (1) a constant region of a human L chain, and (2) FRs of a human L chain, and CDRs of L chain of mouse anti-HM1.24 monoclonal antibody; and (B) H chains each comprising (2) a constant region of a human H chain, and (2) FRs of a human H chain, and CDRs of H chain of mouse anti-HM1.24 monoclonal antibody. Since the majority of the reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, the reshaped human antibody of the present invention has low antigenicity and therefore is very promising in medical and therapeutic applications.
摘要翻译： 重组人抗HM1.24抗体，其包含：（A）L链，其各自包含（1）人L链的恒定区，和（2）人L链的FR和小鼠抗体的L链的CDR， HM1.24单克隆抗体; 和（B）H链，其各自包含（2）人H链的恒定区，和（2）人H链的FR和小鼠抗HM1.24单克隆抗体的H链的CDR。 由于大部分重构人抗体衍生自人抗体，CDR具有低抗原性，因此本发明的重构人抗体具有低抗原性，因此在医学和治疗应用中非常有希望。
-
公开(公告)号：US20060084119A1
公开(公告)日：2006-04-20
申请号：US10509343
申请日：2003-03-28
IPC分类号： G01N33/567 , C07H21/04 , C12P21/06 , C12N5/06 , C07K14/705
CPC分类号： C12N15/86 , A61K38/00 , C07K14/705 , C12N7/00 , C12N2710/14121 , C12N2710/14143 , G01N2333/01 , G01N2500/10
摘要： Methods for measuring transporter activity using budding baculoviruses that do not express endogenous transporters on their envelope have a low background level and can measure the target activity with a high sensitivity. Such methods can be used to measure functional changes due to transporter SNPs over a more extensive range of substrates, and can be applied to tailor-made therapies.
摘要翻译： 使用不在其包膜上表达内源性转运蛋白的芽状杆状病毒测量转运蛋白活性的方法具有低的背景水平并且可以以高灵敏度测量目标活性。 这样的方法可用于测量由于转运体SNP在更广泛的底物范围内的功能变化，并且可以应用于量身定制的疗法。
-
86.发明申请Method for screening compounds inhibiting signal transduction through inflammatory cytokines 审中-公开筛选通过炎性细胞因子抑制信号转导的化合物的方法公开(公告)号：US20060040316A1
公开(公告)日：2006-02-23
申请号：US11261346
申请日：2005-10-27
IPC分类号： C12Q1/68 , G01N33/542 , G01N33/53
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/47 , C12Q1/48 , G01N33/573 , G01N2500/02
摘要： Revealed are that the actions of inflammatory cytokine and the production of inflammatory cytokines such as IL-1 and TNF induced by an inflammatory stimulus as well as the production of other inflammatory cytokines such as IL-6 induced by the former class of inflammatory cytokines are all suppressed by inhibiting the signal transduction through TAK1.
摘要翻译： 显示炎症细胞因子的作用以及由炎症刺激诱导的炎性细胞因子如IL-1和TNF的产生，以及由前一类炎性细胞因子诱导的其它炎性细胞因子如IL-6的产生都是 通过抑制通过TAK1的信号转导来抑制。
-
87.发明授权Method for screening compounds inhibiting signal transduction through inflammatory cytokines 失效筛选通过炎性细胞因子抑制信号转导的化合物的方法公开(公告)号：US06989244B1
公开(公告)日：2006-01-24
申请号：US09830144
申请日：1999-10-21
CPC分类号： C12N9/1205 , A61K38/00 , C07K14/47 , C12Q1/48 , G01N33/573 , G01N2500/02
摘要： The present invention relates to methods of screening for compounds that inhibit signal transduction by inflammatory cytokines. The methods include providing a sample that contains a TAK1 and a TAB1; contacting the sample with a compound; detecting binding between the TAK1 and the TAB1; and selecting the compound if binding between the TAK1 and TAB1 is inhibited in the sample compared to a control.
摘要翻译： 本发明涉及筛选抑制炎性细胞因子信号转导的化合物的方法。 所述方法包括提供含有TAK1和TAB1的样品; 使样品与化合物接触; 检测TAK1和TAB1之间的结合; 并且如果与对照相比，在样品中抑制TAK1和TAB1之间的结合，则选择该化合物。
-
公开(公告)号：US20060008456A1
公开(公告)日：2006-01-12
申请号：US11226325
申请日：2005-09-15
申请人： Masayuki Tsuchiya
发明人： Masayuki Tsuchiya
IPC分类号： A61K39/395 , C07K16/44
CPC分类号： C07K16/464 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/3061 , C07K2317/24 , C07K2317/732 , C07K2319/00
摘要： A reshaped human anti-HM1.24 antibody comprising: (A) L chains each comprising (1) a constant region of a human L chain, and (2) FRs of a human L chain, and CDRs of L chain of mouse anti-HM1.24 monoclonal antibody; and (B) H chains each comprising (2) a constant region of a human H chain, and (2) FRs of a human H chain, and CDRs of H chain of mouse anti-HM1.24 monoclonal antibody. Since the majority of the reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, the reshaped human antibody of the present invention has low antigenicity and therefore is very promising in medical and therapeutic applications.
摘要翻译： 重组人抗HM1.24抗体，其包含：（A）L链，其各自包含（1）人L链的恒定区，和（2）人L链的FR和小鼠抗体的L链的CDR， HM1.24单克隆抗体; 和（B）H链，其各自包含（2）人H链的恒定区，和（2）人H链的FR和小鼠抗HM1.24单克隆抗体的H链的CDR。 由于大部分重构人抗体衍生自人抗体，CDR具有低抗原性，因此本发明的重构人抗体具有低抗原性，因此在医学和治疗应用中非常有希望。
-
公开(公告)号：US20050142635A1
公开(公告)日：2005-06-30
申请号：US10837904
申请日：2004-05-04
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/18 , C07K16/24 , C07K16/26 , C07K16/28 , C07K19/00 , C12N5/10 , C12N15/13 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/577 , C07H21/04 , C12N5/06 , C12N9/64
CPC分类号： C07K16/2866 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.
摘要翻译： 对人IL-6R的重构人抗体包含：（A）包含（1）人L链C区的L链，和（2）包含人L链框架区（FR）的L链V区， 和IL-6受体（IL-6R）的单克隆抗体的小鼠L链互补决定区（CDR）; 和（B）包含（1）人H链C区和（2）包含人H链FRS的H链V区的H链和与IL-6R的单克隆抗体的小鼠H链CDR。 由于重构的人抗体的大部分衍生自人抗体和免疫原性较小的小鼠CDR，所以本发明的重组人抗体对人的免疫原性较低，因此被用于治疗用途。
-
90.发明授权Iron based alloy material for thixocasting process and method for casting the same 有权用于触变过程的铁基合金材料及其铸造方法公开(公告)号：US06863744B2
公开(公告)日：2005-03-08
申请号：US10235855
申请日：2002-09-06
申请人： Masayuki Tsuchiya , Hiroaki Ueno
发明人： Masayuki Tsuchiya , Hiroaki Ueno
IPC分类号： B22D18/02 , B22D17/00 , C22C1/00 , C22C33/08 , C22C37/06 , C22C37/10 , C22C38/00 , C22C38/02 , C22C38/36 , C22C38/34
CPC分类号： C22C33/08 , B22D17/007 , C22C1/005 , C22C37/06 , C22C37/10
摘要： An iron based alloy material for a thixocasting process and a method for casting the material which extends the service life of dies by inhibiting solidification contraction, and in which casting defects such as size variations and cracks can be inhibited. The material comprises 1.6 wt %≦C≦2.5 wt % and 3.0 wt %
摘要翻译： 用于触变过程的铁基合金材料和通过抑制凝固收缩延长模具使用寿命的铸造材料的方法，并且其中可以抑制诸如尺寸变化和裂纹的铸造缺陷。 该材料包含1.6重量％<= C <= 2.5重量％和3.0重量％
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.043 秒)
